Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLOW-FISH: First-in-human imaging study of anti-GD2-800CW in neuroblastoma
2023-507596-22-00Phase 2Suspended
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- Apr 2025
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Anti-GD2-800CW in neuroblastoma, sponsored by Princess Máxima Center for Pediatric Oncology. Primary endpoints: Safety - Anti-GD2-800CW related adverse events not expected from Dinutuximab-alone infusion and Tumor to background ratio (TBR) for fluorescence imaging. Started Apr 2025; status: suspended.
02
Drugs
Anti-GD2-800CW
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on 2023-507596-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507596-22-00.